Healthcare Services

The Medications For Heart Failure Market Growth Influenced By Advancements In SGLT Inhibitor Therapies

April 23, 2026April 26, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Medications For Heart Failure Market Projected To Reach By 2030?

The medications for heart failure market size has experienced strong growth in recent years. It is projected to increase from $10.79 billion in 2025 to $11.53 billion in 2026, at a compound annual growth rate (CAGR) of 6.8%. The expansion during the historic period can be attributed to the growing prevalence of cardiovascular diseases, an aging global population, the rising incidence of hypertension and diabetes, improved access to essential cardiac medications, and the expansion of hospital-based cardiac care.

The market size for medications addressing heart failure is predicted to show robust expansion over the coming years. It is projected to achieve a value of $15.03 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.8%. This anticipated growth during the forecast period is driven by factors such as an expanding heart failure patient population, the increasing adoption of novel drug classes, a rising emphasis on personalized cardiovascular therapy, the expansion of outpatient and home-based care models, and a stronger focus on preventive cardiology. Prominent trends throughout this period include the rising adoption of combination drug therapies, the growing utilization of SGLT2 inhibitors in heart failure treatment, an increasing focus on early diagnosis and long-term disease management, the broadening of evidence-based treatment guidelines, and a higher emphasis on reducing heart failure hospitalizations.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24315&type=smp

What Leading Drivers Are Supporting The Medications For Heart Failure Market Expansion?

An increasing occurrence of cardiovascular ailments is anticipated to drive expansion within the medications for the heart failure market in the future. These diseases are defined as conditions affecting the heart and blood vessels, frequently leading to serious complications like heart attacks and strokes. The increase in cardiovascular disorders primarily stems from inactive lifestyles, which progressively diminish the health of the heart and blood vessels. With the escalating rates of cardiovascular disease, the need for efficacious treatments expands, stimulating increased investment in heart failure medications. As this condition becomes more prevalent, pharmaceutical firms are focusing on advancing and refining therapies to better control symptoms and enhance patient results. For example, in September 2024, the Heart Failure Society of America (HFSA), a US-based group of heart failure specialists, reported that approximately 6.7 million Americans aged 20 and older currently have heart failure (HF), and this figure is expected to reach 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. Consequently, the growing occurrence of cardiovascular diseases is propelling the expansion of medications within the heart failure market.

How Is The Medications For Heart Failure Market Segmented Across Different Segment Categories?

The medications for heart failure market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Beta Blockers, Diuretics, Aldosterone Antagonists, Angiotensin II Receptor Blockers (ARBs), Other Drug Classes

2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administrations

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril, Captopril, Perindopril

2) By Beta Blockers: Carvedilol, Metoprolol Succinate, Bisoprolol, Nebivolol

3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Angiotensin II Receptor Blockers (ARBs): Valsartan, Losartan, Candesartan, Irbesartan

6) By Other Drug Classes: Angiotensin Receptor-Neprilysin Inhibitors, Ivabradine, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Hydralazine Or Isosorbide Dinitrate, Digoxin

What Emerging Trends Are Seen In The Medications For Heart Failure Market?

Major companies within the medication for heart failure market are concentrating on creating sophisticated drugs, including sodium-glucose cotransporter (SGLT) inhibitors, to offer more potent long-term handling of heart failure indications and related issues. An SGLT inhibitor functions as an advanced medicine by targeting glucose reabsorption pathways to control heart failure, boost effectiveness, and improve cardiovascular health. For example, in May 2023, Lexicon Pharmaceuticals, a US-based biopharmaceutical firm, launched Inpefa (sotagliflozin), following its approval by the Food and Drug Administration (FDA). This once-daily oral tablet is formulated to lower the chances of cardiovascular mortality, hospital admission due to heart failure, and urgent visits for heart failure in adults experiencing heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk elements. The FDA’s endorsement represents a notable achievement for Lexicon, given that Inpefa is the first dual SGLT1/SGLT2 inhibitor to become available, providing an innovative treatment pathway for heart failure sufferers across diverse health circumstances.

Which Organizations Play A Role In The Medications For Heart Failure Market Landscape?

Major companies operating in the medications for heart failure market are Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals Inc., CSPC Pharmaceutical, Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals, Ionis Pharmaceuticals Inc., Hainan Poly Pharm Co Ltd, Lunan Pharmaceutical Group, Mylan Laboratories Inc., JM Laboratories, Lexicon Pharmaceuticals, Pfizer Inc, Johnson & Johnson, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Amgen Inc, Otsuka Pharmaceutical Co Ltd

Get The Full Medications For Heart Failure Market Report:

https://www.thebusinessresearchcompany.com/report/medications-for-heart-failure-global-market-report

Which Region Accounts For The Largest Portion Of The Medications For Heart Failure Market?

North America was the largest region in the medications for the heart failure market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medications for heart failure market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Medications For Heart Failure Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/medications-for-heart-failure-global-market-report

Browse Through More Reports Similar to the Global Medications For Heart Failure Market 2026, By The Business Research Company

Pharmaceuticals Market

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Therapeutic Drug Monitoring Market Report

https://www.thebusinessresearchcompany.com/report/therapeutic-drug-monitoring-global-market-report

Patient Centric Healthcare App Market Report

https://www.thebusinessresearchcompany.com/report/patient-centric-healthcare-app-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795